188 related articles for article (PubMed ID: 24231406)
1. The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.
Fugit KD; Anderson BD
J Control Release; 2014 Jan; 174():88-97. PubMed ID: 24231406
[TBL] [Abstract][Full Text] [Related]
2. Ion-Pairing Contribution to the Liposomal Transport of Topotecan as Revealed by Mechanistic Modeling.
Fugit KD; Anderson BD
J Pharm Sci; 2017 Apr; 106(4):1149-1161. PubMed ID: 28007561
[TBL] [Abstract][Full Text] [Related]
3. Insights into accelerated liposomal release of topotecan in plasma monitored by a non-invasive fluorescence spectroscopic method.
Fugit KD; Jyoti A; Upreti M; Anderson BD
J Control Release; 2015 Jan; 197():10-9. PubMed ID: 25456833
[TBL] [Abstract][Full Text] [Related]
4. Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions.
Modi S; Xiang TX; Anderson BD
J Control Release; 2012 Sep; 162(2):330-9. PubMed ID: 22800581
[TBL] [Abstract][Full Text] [Related]
5. Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH.
Joguparthi V; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):433-54. PubMed ID: 17918731
[TBL] [Abstract][Full Text] [Related]
6. F7 and topotecan co-loaded thermosensitive liposome as a nano-drug delivery system for tumor hyperthermia.
Du C; Li S; Li Y; Galons H; Guo N; Teng Y; Zhang Y; Li M; Yu P
Drug Deliv; 2020 Dec; 27(1):836-847. PubMed ID: 32508162
[TBL] [Abstract][Full Text] [Related]
7. A Novel Polymer-Lipid Hybrid Nanoparticle for the Improvement of Topotecan Hydrochloride Physicochemical Properties.
Silva EJ; Souza LG; Silva LAD; Taveira SF; Guilger RC; Liao LM; Queiroz Junior LHK; Santana MJ; Marreto RN
Curr Drug Deliv; 2018; 15(7):979-986. PubMed ID: 29243576
[TBL] [Abstract][Full Text] [Related]
8. Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform.
Saraf S; Jain A; Hurkat P; Jain SK
Crit Rev Ther Drug Carrier Syst; 2016; 33(5):401-432. PubMed ID: 27910741
[TBL] [Abstract][Full Text] [Related]
9. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.
Gilabert-Oriol R; Chernov L; Anantha M; Dragowska WH; Bally MB
Drug Deliv Transl Res; 2017 Aug; 7(4):544-557. PubMed ID: 28432657
[TBL] [Abstract][Full Text] [Related]
10. Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67.
Joguparthi V; Xiang TX; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):400-20. PubMed ID: 17879989
[TBL] [Abstract][Full Text] [Related]
11. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
12. Activity of Topotecan toward the DNA/Topoisomerase I Complex: A Theoretical Rationalization.
Bali SK; Marion A; Ugur I; Dikmenli AK; Catak S; Aviyente V
Biochemistry; 2018 Mar; 57(9):1542-1551. PubMed ID: 29412654
[TBL] [Abstract][Full Text] [Related]
13. Copper-topotecan complexation mediates drug accumulation into liposomes.
Taggar AS; Alnajim J; Anantha M; Thomas A; Webb M; Ramsay E; Bally MB
J Control Release; 2006 Aug; 114(1):78-88. PubMed ID: 16842880
[TBL] [Abstract][Full Text] [Related]
14. pH-sensitive liposomes bearing a chemotherapeutic agent and a natural apoptosis modulator for effective intracellular delivery to the solid tumor.
Saraf S; Jain SK
Drug Deliv Transl Res; 2023 Dec; 13(12):2961-2981. PubMed ID: 37306925
[TBL] [Abstract][Full Text] [Related]
15. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
[TBL] [Abstract][Full Text] [Related]
16. Structural spectroscopy and dynamics of inter- and intramolecular H-bonding interactions of topotecan, a potent anticancer drug, in organic solvents and in aqueous solution.
di Nunzio MR; Wang Y; Douhal A
J Phys Chem B; 2012 Jun; 116(25):7522-30. PubMed ID: 22662747
[TBL] [Abstract][Full Text] [Related]
17. An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.
Jyoti A; Fugit KD; Sethi P; McGarry RC; Anderson BD; Upreti M
Sci Rep; 2015 Oct; 5():15236. PubMed ID: 26468877
[TBL] [Abstract][Full Text] [Related]
18. Influence of intravesicular pH drift and membrane binding on the liposomal release of a model amine-containing permeant.
Tejwani RW; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):381-99. PubMed ID: 17694543
[TBL] [Abstract][Full Text] [Related]
19. Engineered liposomes bearing camptothecin analogue for tumour targeting:
Saraf S; Jain A; Tiwari A; Verma A; Jain SK
J Liposome Res; 2021 Dec; 31(4):326-341. PubMed ID: 32718195
[TBL] [Abstract][Full Text] [Related]
20. Topotecan effect on the structure of normal and cancer plasma membrane lipid models: A multi-model approach.
Lopes-de-Araújo J; Reis S; Nunes C
Eur J Pharm Sci; 2018 Oct; 123():515-523. PubMed ID: 30086354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
